New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 28, 2014
16:19 EDTFLXNFlexion signs worldwide exclusive license with Southwest Research Institute
Flexion Therapeutics announced that it has executed an exclusive worldwide licensing agreement with the Southwest Research Institute, or SwRI, to utilize proprietary microsphere manufacturing technologies for production of Flexion's sustained-release drug candidates, including leading candidate FX006. The SwRI technologies employ a uniquely controlled and continuous atomizing technology that Flexion believes may facilitate efficient scale-up of phase 3 clinical trial material and commercial supply. Flexion has successfully used this technology to produce clinical trial microsphere product for its lead drug candidate FX006, which has been tested in more than 200 patients.
News For FLXN From The Last 14 Days
Check below for free stories on FLXN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 18, 2014
09:07 EDTFLXNFlexion trial likely to be allowed to continue, says Summer Street
Subscribe for More Information
06:19 EDTFLXNFlexion to host conference call
Conference call to discuss clinical hold of FX006 phase 2b clinical trial in Osteoarthritis of the knee will be held on September 18 at 9 am. Webcast Link
September 17, 2014
18:29 EDTFLXNOn The Fly: After Hours Movers
Subscribe for More Information
16:10 EDTFLXNFlexion drops 18% to $15.83 after FDA places clinical hold on study
Subscribe for More Information
16:08 EDTFLXNFlexion announces clinical hold on Phase 2b trial enrollment
Flexion Therapeutics announced that the FDA informed the company yesterday that a clinical hold has been placed on patient enrollment and dosing in an ongoing Phase 2b clinical trial evaluating FX006 in patients with osteoarthritis of the knee. FX006 is a novel, non-opioid, sustained-release, intra-articular formulation of triamcinolone acetonide targeting moderate-to-severe OA pain. Flexion said it has not yet received written notice of its clinical hold from the FDA, but based on the verbal communication yesterday afternoon, the FDA indicated that the clinical hold is due to a single occurrence of an infection in the injected knee joint of a patient in the Phase 2b clinical trial.
September 9, 2014
16:12 EDTFLXNFlexion issued composition of matter patent for lead candidate FX006
Flexion Therapeutics announced that the U.S. Patent and Trademark Office has issued a composition of matter patent, entitled "Corticosteroids for the Treatment of Joint Pain," which provides coverage for FX006, the company's lead clinical product candidate. FX006 is a novel, non-opioid, sustained-release, intra-articular formulation of triamcinolone acetonide.
September 5, 2014
08:53 EDTFLXNFlexion price target raised to $28 from $25 at Summer Street
Subscribe for More Information
September 4, 2014
09:05 EDTFLXNFlexion FDA guidance a 'significant positive,' says Summer Street
Subscribe for More Information
06:58 EDTFLXNFlexion to host conference call
Conference call to discuss an update on the new clinical development plan for FX006 will be held on September 4 at 8:30 am. Webcast Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use